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Evaluation (GRADE) approach using the example of male human papilloma virus 
(HPV) vaccination Europe. Methods: A pan-European multidisciplinary expert 
group was established to develop an extended GRADE framework that includes 
explicit assessment of cost-effectiveness, medical needs, and patient aspects, ethi-
cal and social issues. Using an expert panel process, we assessed the feasibility of 
using this framework by applying it to male HPV vaccination in Europe. Studies were 
assessed using the specific framework tools; results and feasibility were discussed; 
and consensus was achieved through a modified Delphi method. Results: We 
identified three advisory committees (ACIP/USA; NACI/Canada; STIKO/Germany) 
using GRADE for vaccines assessment. Institutions handled data beyond vaccine 
efficacy and safety differently and did not formally grade economic evidence. We 
adopted the grading methodology of ACIP for the key factor ‘Benefits and Harms’ 
and developed modules for grading evidence type and quality of economic evalua-
tions (‘Economic Evaluation’) and for systematically assessing epidemiology, disease 
burden and unmet medical needs, as well as ethical, social and patient aspects 
(‘Values and Preferences’). The feasibility test demonstrated that all framework 
components were feasible in the case of HPV vaccination. Overall evidence type 
for cost-effectiveness was low with uncertainty in results. Cost-effectiveness was 
best, when all HPV-related diseases and outcomes were included and when assum-
ing low coverage in females and lower vaccine prices. ConClusions: The GRADE 
approach is applicable in assessing vaccinations and was successfully applied to 
HPV vaccination in males. The assessment of benefits and harms can be extended 
by explicit assessment of the evidence on cost-effectiveness and other key fac-
tors including unmet medical needs, and ethical, social and patient aspects. This 
extended framework can better inform policy- and decison makers.
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objeCtives: Modelling is essential in performing economic evaluations for various rea-
sons. For example, modelling is necessary if extrapolation of short-term or intermediate 
results to long-term outcomes is required and numerous strategies need to be evaluated 
without direct evidence. However, modelling inherently poses challenges that need to 
be dealt with since models always represent a simplification of reality. The aim of this 
study is to identify and analyse the challenges in modelling the cost-effectiveness of 
cardiovascular disease (CVD) interventions. Methods: A questionnaire was sent to 
40 corresponding authors (systematically selected) of recent model-based economic 
evaluations of CVD interventions published in high-impact cardiovascular, health eco-
nomics and general medical journals. Respondents were asked to provide their own 
challenges and also rank the importance of challenges identified using a pilot version 
of the questionnaire distributed to 7 experienced researchers. Furthermore, we analysed 
the discussion sections of the papers to identify unmentioned challenges. Solutions, 
if available, were based on input from the respondents and the recommendations of 
the ISPOR-SMDM task force. Results: The systematic literature search identified 1720 
potentially relevant articles. The limit of 40 authors was reached after screening 294 
titles and abstracts. Beside the challenge of lack of data, preliminary results show that 
it was difficult to obtain a sufficiently valid, precise and accurate cost-effectiveness 
estimate due, for example, to interrelating clinical outcomes or extrapolating from sur-
rogate outcomes. Both challenges often exist in CEAs evaluating CVD prevention strate-
gies. ConClusions: The preliminary results of this study showed examples of CVD 
modelling challenges encountered during studies published in high-impact journals. 
Modelling guidelines do not provide sufficient assistance in resolving all challenges 
but it is probably unrealistic to expect this. Some of the reported challenges are specific 
to the type of intervention and disease, but most challenges are present in all types of 
interventions and diseases.
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objeCtives: There is general support that individual time preference affects health-
related behaviours. People with a high, positive time preference value their imme-
diate health higher than future health, even if presented with extreme scenarios 
of intertemporal choice. We hypothesised that adherence to medication requires 
trade-offs between immediate and delayed health benefits. Patients with lower 
time preference rates may be more adherent to medication as they place a higher 
value on the future benefits of adherence. Methods: Hypertensive adult patients 
across Europe were invited to complete a web-based survey that had been translated 
and piloted. Patients’ time preference was assessed (4-items) to calculate individual 
discount rates (%) in both short term (3-years) and medium term (6-years). Medication 
adherence was measured using the Morisky questionnaire (primary analysis) and the 
Medication Adherence Report Scale (MARS, secondary analysis). Sample size calculation, 
based on 5% one-sided confidence, assuming 30% non-adherence with Morisky measure 
indicated n= 323 per country. Missing data were imputed using multiple imputation in 
STATA. The significance of the association with adherence was assessed using the Wald 
test statistic. Results: 969 patients completed the questionnaire across England, Wales 
and Hungary, 79% of possible responses were observed. Short and medium term time 
preference rates in England, Wales and Hungary were in the expected directions, but 
the relationship was not statistically significant. Based on Morisky adherence - Wales 
(short): adherent 8.7%, non-adherent 9.4% (p= 0.541); (medium): adherent 4.7%, non-
adherent 5.0% (p= 0.611). England (short): adherent 7.8%, non-adherent 9.5% (p= 0.163); 
(medium): adherent 3.7%, non-adherent 4.5% (p= 0.095). Hungary (short): adherent 
19.0%, non-adherent 18.2% (p= 0.504); (medium): adherent 8.9%, non-adherent 8.6% 
to derive OS estimates for nilotinib and dasatinib of 13.0 and 13.4 years respectively 
(second-line CP). Using the same approach for bosutinib gives an OS of 12.8 years 
(third-line CP). The base-case in TA251 used a cumulative approach, where OS is 
equal to the duration of treatments in the pathway. If this method is applied to the 
TKIs in second-line CML (TA241), OS is reduced to approximately 9.4 and 10.1 years 
for nilotinib and dasatinib respectively (second-line CP). Similarly, bosutinib OS 
(third-line CP) is also reduced using this method and a substantial increase in the 
ICER is seen. ConClusions: There are methodological inconsistencies in NICE’s 
assessments of TKIs for CML. Applying the OS methodology from TA251 to TA241 
may have led to nilotinib not being recommended for routine use in the NHS. The 
impact of new methodologies on previous appraisal results and recommendations 
should be considered when assessing the validity of a new approach.
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objeCtives: To evaluate differences across randomized controlled trials (RCTs) con-
cerning interventions for moderate to severe chronic obstructive pulmonary disease 
(COPD) in terms of baseline exacerbation rates and the association with treatment 
effects by means of a network meta-analysis (NMA). This NMA is performed based on 
RCTs evaluating the long-acting bronchodilators indacaterol 75/150/300µg OD, salme-
terol 50µg BID, formoterol 12µg BID, tiotropium bromide 18µg/5µg OD, and glycopyr-
ronium bromide 50µg OD. Methods: The rate of moderate or severe exacerbations 
was extracted from RCTs identified with a systematic literature review. A Bayesian NMA 
was used to synthesize the treatment effects of the different trials. The association 
between treatment effects and baseline exacerbation rate with placebo was assessed 
with a meta-regression model assuming a constant treatment-by-baseline risk interac-
tion term. Results: Twenty-four RCTs were included that differed mainly in terms of 
smoking status, COPD severity, use of inhaled corticosteroids, exacerbation definition, 
and exacerbation history. Across the RCTs the rate of exacerbations per patient year for 
patients in the placebo arm ranged from 0.40 to 1.91. Baseline risk was negatively associ-
ated with the rate ratios reflecting treatment effects across the RCTs. The coefficient for 
baseline risk was -0.35 (95% credible intervals: -0.49, -0.18). ConClusions: Based on a 
NMA of RCTs regarding the efficacy of long-acting bronchodilators in terms of the rate 
of exacerbations per patient year, baseline risk of exacerbations acts as a significant 
treatment effect modifier and should be accounted for in the model.
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objeCtives: Licensing and reimbursement of anticancer drugs should rely on evi-
dence from patient-relevant endpoints such as overall survival (OS). Nevertheless, 
evidence from surrogate endpoints may also be useful, as it may expedite the regula-
tory approval and coverage decisions of new therapies. It is therefore essential that 
candidate surrogate endpoints be properly validated. However, there is no consensus 
on statistical methods for such validation and on how the evidence thus derived 
should be applied by policy makers. Methods: We review meta-analyses of thera-
peutic interventions against advanced solid tumours published until December 2012 
that quantified the statistical association between progression-free survival (PFS) 
or time-to-progression (TTP) and OS. We assessed the suitability of the two surro-
gates using three current surrogate validation frameworks: Bucher’s framework, the 
German Institute of Quality and Efficiency in Health Care’s (IQWiG) framework and 
the Biomarker-Surrogacy Evaluation Schema (BSES3). Results: Thirty-one meta-
analyses were included which employed a variety of statistical methods to assess 
surrogate validity. The strength of the association between PFS or TTP and OS was 
generally low. The level of evidence (observation-level vs. treatment-level) available 
supporting an association between PFS or TTP and OS varied considerably by cancer 
type, by evaluation tools and was not always consistent even within one specific 
cancer type. ConClusions: Not in all solid tumours the treatment-level associa-
tion between PFS or TTP and OS has been investigated. According to the IQWiG’s 
framework, only PFS achieved acceptable evidence of surrogacy in metastatic colo-
rectal and ovarian cancer treated with cytotoxic agents, whereas in no indication 
did the two candidate endpoints achieve good evidence of surrogacy according to 
BSES3. Our study emphasises the challenges of surrogate-endpoint validation and 
the importance of building consensus on appropriate statistical techniques to exam-
ine surrogacy and on the development of evaluation frameworks for policy makers.
Cl4
framework for evidenCe assessment Based on grade and 
appliCation to hpv vaCCination in males in the european health 
Care Context
Siebert U.1, Sroczynski G.2, Baker P.3, Borget I.4, Castellsagué X.5, Chapman R.6,  
von Knebel-Doeberitz M.7, Mortensen G.L.8, La Torre G.9
1UMIT – University for Health Sciences, Medical Informatics and Technology / ONCOTYROL / Harvard 
University, Hall i. T./ Innsbruck / Boston, Austria, 2UMIT – University for Health Sciences, Medical 
Informatics and Technology, Hall i.T., Austria, 3Men’s Health Consultant, Brighton, UK, 4Institut 
Gustave Roussy, Villejuif, France, 5L’Hospitalet de Llobregat, Barcelona, Spain, 6Evidera, London, UK, 
7University of Heidelberg, German Cancer Research Center, Heidelberg, Germany, 8AnthroConsult, 
Aarhus C, Denmark, 9Sapienza University of Rome, Rome, Italy
objeCtives: To develop and apply an extended framework for evidence assess-
ment based on the Grading of Recommendations Assessment, Development and 
